<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03552003</url>
  </required_header>
  <id_info>
    <org_study_id>FIL_ELDHL</org_study_id>
    <nct_id>NCT03552003</nct_id>
  </id_info>
  <brief_title>Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis</brief_title>
  <official_title>Prospective Study on Elderly (≥ 65 Years) Patients Affected With Classical Hodgkin Lymphoma Undergoing Comprehensive Geriatric Assessment at Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to develop a prognostic index for elderly patients with newly
      diagnosed cHL starting from a prospective observational study of consecutive cases registered
      after the completion of the Comprehensive Geriatric Assessment (CGA)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to develop a prognostic index for elderly patients with newly
      diagnosed cHL starting from a prospective observational study of consecutive cases registered
      after the completion of the Comprehensive Geriatric Assessment (CGA) Prospective data
      collection study of a consecutive series of newly diagnosed elderly cHL patients undergoing
      CGA before any therapy with the use of ADL, IADL and CIRS-G. Patients who will be considered
      not eligible to receive treatment or to be given only palliative therapy after CGA assessment
      are eligible for the study. Patients will be screened and restaged according to clinical
      practice instrumental and laboratory assessments timing and type of examinations.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>June 2018-December 2025 (7.5 years)</time_frame>
    <description>Overall survival (OS). From the date of diagnosis to the date of last observation or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>June 2018-December 2025 (7.5 years)</time_frame>
    <description>Progression Free Survival (PFS): From the date of diagnosis to the last follow-up, or to one of the following events: disease progression during treatment, or relapse, or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FFS</measure>
    <time_frame>June 2018-December 2025 (7.5 years)</time_frame>
    <description>Failure Free Survival (FFS). From the date of diagnosis to to any treatment failure including disease progression, or discontinuation of treatment for any reason, (eg, disease progression, toxicity, patient preference, initiation of new treatment), or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response initial therapy</measure>
    <time_frame>June 2018-January 2024 (5.5 years, 6-7 month after the enrolment)</time_frame>
    <description>Response initial therapy: Rate of complete remission (CR) after chemotherapy +/-RT, according to Cheson 2007</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Classical Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Newly diagnosed elderly cHL patients</arm_group_label>
    <description>Newly diagnosed elderly cHL patients undergoing CGA before any therapy (treatment for clinical practise) with the use of ADL, IADL and CIRS-G. Patients who will be considered not eligible to receive treatment or to be given only palliative therapy after CGA assessment are eligible for the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment for clinical practise</intervention_name>
    <description>Prospective data collection with the aim to to develop a prognostic index for elderly patients with newly diagnosed cHL</description>
    <arm_group_label>Newly diagnosed elderly cHL patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Mandatory:

      1) paraffin block for diagnosis review

      Optional:

        1. paraffin block for TISSUE MICRO ARRAYS analyses

        2. 3ml blood adsorbed on a swab tip for IMMUNO SENESCENCE AND FRAILTY evaluation

        3. 3ml blood adsorbed on a swab tip for IMMUNO SENESCENCE AND TORQUE TENO VIRUS evaluation
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        newly diagnosed elderly cHL patients undergoing CGA before any therapy with the use of ADL,
        IADL and CIRS-G. Patients who will be considered not eligible to receive treatment or to be
        given only palliative therapy after CGA assessment are eligible for the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of classical Hodgkin Lymphoma

          2. Age ≥ 65 year

          3. Evaluation of Comprehensive Geriatric Assessment at baseline

          4. Signed informed consent

          5. Previously untreated patients

        Exclusion Criteria:

        None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vittorio Ruggero Zilioli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SC Ematologia, ASST Grande Ospedale Metropolitano Niguarda, Milano - Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vittorio Ruggero Zilioli, MD</last_name>
    <phone>+39 02 64442668</phone>
    <email>vittorioruggero.zilioli@ospedaleniguarda.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>SC Ematologia AO SS. Antonio e Biagio e C. Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Manuela Zanni, MD</last_name>
      <email>manuela.zanni@ospedale.al.it</email>
    </contact>
    <investigator>
      <last_name>Manuela Zanni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Politecnica delle Marche - Clinica di Ematologia</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Guido Gini, MD</last_name>
      <email>guido.gini@ospedaliriuniti.marche.it</email>
    </contact>
    <investigator>
      <last_name>Guido Gini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giuseppe Rodolfo Nunziata, MD</last_name>
      <email>grnunziata@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Rodolfo Nunziata, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Riferimento Oncologico - S.O.C. Oncologia Medica A</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Michele Spina, MD</last_name>
      <email>mspina@cro.it</email>
    </contact>
    <investigator>
      <last_name>Michele Spina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Consorziale - U.O. Ematologia con Trapianto</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giorgina Specchia, Prof</last_name>
      <email>giorgina.specchia@uniba.it</email>
    </contact>
    <investigator>
      <last_name>Giorgina Specchia, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Monsignor Raffaele Dimiccoli&quot; - Ematologia</name>
      <address>
        <city>Barletta</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giuseppe Tarantini, MD</last_name>
      <email>giuseppetarantini0@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Tarantini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Spedali Civili di Brescia - Ematologia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Alessandra Tucci, MD</last_name>
      <email>alessandra.tucci@asst-spedalicivili.it</email>
    </contact>
    <investigator>
      <last_name>Alessandra Tucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Businco - Ematologia</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Stefania Massidda, MD</last_name>
      <email>smassidda@email.it</email>
    </contact>
    <investigator>
      <last_name>Stefania Massidda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Ematologia</name>
      <address>
        <city>Campobasso</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Sergio Storti, MD</last_name>
      <email>sergio.storti@unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Sergio Storti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Castelfranco Veneto - Ematologia</name>
      <address>
        <city>Castelfranco Veneto</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Roberto Sartori, MD</last_name>
      <email>roberto.sartori@aulss2.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Sartori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Cosenza - UOC Ematologia</name>
      <address>
        <city>Cosenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Massimo Gentile, MD</last_name>
      <email>massimogentile@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Massimo Gentile, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Luigi Rigacci, MD</last_name>
      <email>luigi.rigacci@unifi.it</email>
    </contact>
    <investigator>
      <last_name>Luigi Rigacci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia PO Spaziani</name>
      <address>
        <city>Frosinone</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Alessandro Andriani, MD</last_name>
      <email>alessandro.andriani1@tin.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Andriani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti del Canavese - S.C. Medicina trasfusionale ed Ematologia</name>
      <address>
        <city>Ivrea</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Roberto Freilone, MD</last_name>
      <email>rfreilone@aslto4.piemonte.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Freilone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Madonna delle Grazie - Ematologia</name>
      <address>
        <city>Matera</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Alberto Fragasso, MD</last_name>
      <email>alberto.fragasso@libero.it</email>
    </contact>
    <investigator>
      <last_name>Alberto Fragasso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Gerardo Musuraca, MD</last_name>
      <email>g.musuraca@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Gerardo Musuraca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Vittorio Ruggero Zilioli, MD</last_name>
      <email>vittorioruggero.zilioli@ospedaleniguarda.it</email>
    </contact>
    <investigator>
      <last_name>Vittorio Ruggero Zilioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico San Raffaele - Unità Linfomi - Dipartimento Oncoematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrés Ferreri, MD</last_name>
      <email>andres.ferreri@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Andrés Ferreri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda - Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Francesca Gaia Rossi, MD</last_name>
      <email>francescagaia.rossi@policlinico.mi.it</email>
    </contact>
    <investigator>
      <last_name>Francesca Gaia Rossi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Università degli Studi della Campania Luigi Vanvitelli - Oncologia Medica ed Ematologia</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Antonello Sica, MD</last_name>
      <email>antonello.sica@fastwebnet.it</email>
    </contact>
    <investigator>
      <last_name>Antonello Sica, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Maggiore della Carità di Novara - SCDU Ematologia</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Luca Nassi, MD</last_name>
      <email>luca.nassi@med.uniupo.it</email>
    </contact>
    <investigator>
      <last_name>Luca Nassi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU di Padova - Ematologia</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Livio Trentin, MD</last_name>
      <email>livio.trentin@unipd.it</email>
    </contact>
    <investigator>
      <last_name>Livio Trentin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S. Istituto Oncologico Veneto - Oncologia 1</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Dario Marino, MD</last_name>
      <email>dario.marino@iov.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Dario Marino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Giaccone - Ematologia</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Salvatrice Mancuso, MD</last_name>
      <email>salvatrice.mancuso@unipa.it</email>
    </contact>
    <investigator>
      <last_name>Salvatrice Mancuso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU di Parma - UO Ematologia e CTMO</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Francesca Re, MD</last_name>
      <email>fre@ao.pr.it</email>
    </contact>
    <investigator>
      <last_name>Francesca Re, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Maria della Misericordia - Ematologia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Leonardo Flenghi, MD</last_name>
      <email>flenghi@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Leonardo Flenghi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Guglielmo da Saliceto - U.O. Ematologia</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Annalisa Arcari, MD</last_name>
      <email>a.arcari@ausl.pc.it</email>
    </contact>
    <investigator>
      <last_name>Annalisa Arcari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale delle Croci - Ematologia</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Monica Tani, MD</last_name>
      <email>monica.tani@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Monica Tani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Francesco Merli, MD</last_name>
      <email>merli.francesco@ausl.re.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Merli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi di Rimini - U.O. di Ematologia</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Anna Lia Molinari, MD</last_name>
      <email>annalia.molinari@auslromagna.it</email>
    </contact>
    <investigator>
      <last_name>Anna Lia Molinari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Sant'Andrea - Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria Christina Cox, MD</last_name>
      <email>chrisscox@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Christina Cox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Cattolica S. Cuore - Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Stefan Hohaus, Prof</last_name>
      <email>stefan.hohaus@Unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Stefan Hohaus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas - U.O. Ematologia</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Francesca Ricci, MD</last_name>
      <email>francesca.ricci@humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Francesca Ricci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nuovo Ospedale Civile di Sassuolo - Day Hospital Oncologico</name>
      <address>
        <city>Sassuolo</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Sara Bigliardi, MD</last_name>
      <email>s.bigliardi@ospedalesassuolo.it</email>
    </contact>
    <investigator>
      <last_name>Sara Bigliardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Senese - U.O.C. Ematologia</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Alberto Fabbri, MD</last_name>
      <email>fabbri7@unisi.it</email>
    </contact>
    <investigator>
      <last_name>Alberto Fabbri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera della Valtellina e della Valchiavenna P.O. Sondrio - Medicina Interna - Centro Malattie del Sangue P.O. Sondrio</name>
      <address>
        <city>Sondrio</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrea Maria Soccodato, MD</last_name>
      <email>andresocco@alice.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Maria Soccodato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. S. Maria di Terni - S.C. Oncoematologia</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Anna Marina Liberati, Prof</last_name>
      <email>marina.liberati@unipg.it</email>
    </contact>
    <investigator>
      <last_name>Anna Marina Liberati, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Citta della Salute e della Scienza di Torino - Ematologia Universitaria</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Federica Cavallo, MD</last_name>
      <email>f.cavallo@unito.it</email>
    </contact>
    <investigator>
      <last_name>Federica Cavallo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. Citta della Salute e della Scienza di Torino - S.C. Ematologia</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Barbara Botto, MD</last_name>
      <email>bbotto@cittadellasalute.to.it</email>
    </contact>
    <investigator>
      <last_name>Barbara Botto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. C. Panico - U.O.C Ematologia e Trapianto</name>
      <address>
        <city>Tricase</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Vincenzo Pavone, MD</last_name>
      <email>salentoematologia@piafondazionepanico.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Pavone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 29, 2018</study_first_submitted>
  <study_first_submitted_qc>May 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2018</study_first_posted>
  <last_update_submitted>June 12, 2018</last_update_submitted>
  <last_update_submitted_qc>June 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hodgkin</keyword>
  <keyword>Elderly patients</keyword>
  <keyword>CGA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

